Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPO-RAs and anti-CD20 antibody in adult ITP with autoantibodies
NCT04915482Phase 3Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of eltrombopag, hetrombopag, avatrombopag, rituximab, Ortuzumab in immune thrombocytopenia (ITP), Evans syndrome, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jun 2021; status: recruiting.
02
Drugs
eltrombopaghetrombopagavatrombopagrituximabOrtuzumab
03
Conditions
immune thrombocytopenia (ITP)Evans syndrome
Beyond the preview
Go deeper on NCT04915482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915482.